5225 (5225) Fair Value & Analysis
Healthcare · MY · Market cap 76.9B MYR
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 4.87 MYR to 5.23 MYR (+7.4%) since Jun 23, 2026. Share price −6.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 6.56 MYR – 9.51 MYR · fair‑value band 2.88 MYR – 6.54 MYR · the 8.56 MYR price screens above the 5.23 MYR fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
5225 (5225) currently trades at 8.56 MYR, while our model-based Fair Value estimate is 5.23 MYR — implying the stock looks roughly 38.9% overvalued today. We read business quality at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, 5225 generated revenue of 26.0B MYR at a net margin of 8.1%. Revenue grew 4.1% year over year. It earns a return on equity of 7.9%. Net debt stands at 15.9B MYR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary care facilities, including medical emergencies and acute treatment, as well as specialist consultation, diagnostics, and lab services; tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, laboratory testing, radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, c…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
5225 reported revenue of 25.7B MYR in FY2025 versus 17.1B MYR in FY2021, a compound +10.7%/yr. Reported net income was 2.1B MYR in FY2025, compounding +3.1%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
| Fresenius Medical Care AG FMS | $23.70 | $45.51 | +92% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 5225 (5225) undervalued?
What is the fair value of 5225?
What is the quality score of 5225?
What is the revenue of 5225 (5225)?
What is the net profit margin of 5225?
Does 5225 pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.